A Safety Study of SGN-LIV1A in Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

October 22, 2013

Primary Completion Date

February 4, 2023

Study Completion Date

February 4, 2023

Conditions
HER2 Positive Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsTriple Negative Breast NeoplasmsHER2 Mutations Breast Neoplasms
Interventions
DRUG

ladiratuzumab vedotin

LV will be given into the vein (IV; intravenously)

DRUG

Trastuzumab

Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)

Trial Locations (38)

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medicine, New York

21201

University of Maryland, Baltimore

26506

West Virginia University, Morgantown

27157

Wake Forest Baptist Medical Center / Wake Forest University, Winston-Salem

30309

Piedmont Cancer Institute, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

35249

University of Alabama at Birmingham, Birmingham

37203

Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville

44106

Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland

44195

The Cleveland Clinic, Cleveland

46202

Indiana University Simon Cancer Center, Indianapolis

48201

Karmanos Cancer Institute / Wayne State University, Detroit

55407

Allina Health Cancer Institute, Minneapolis

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic Rochester, Rochester

60637

University of Chicago Medical Center, Chicago

63110

Washington University in St Louis, St Louis

70112

Louisiana State University Health Sciences Center, New Orleans

75246

Texas Oncology - Baylor Sammons Cancer Center, Dallas

78130

Cancer Care Centers of South Texas - HOAST/Texas Oncology, New Braunfels

80012

Rocky Mountain Cancer Centers - Aurora, Aurora

80528

Poudre Valley Health System (PVHS), Fort Collins

85258

Pinnacle Oncology Hematology, Scottsdale

87131

University of New Mexico Cancer Center, Albuquerque

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90048

Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute, Los Angeles

90404

UCLA Medical Center / David Geffen School of Medicine, Santa Monica

92093

UC San Diego / Moores Cancer Center, La Jolla

94134

University of California at San Francisco, San Francisco

97239

Oregon Health and Science University, Portland

98104

Swedish Cancer Institute, Seattle

98109

Seattle Cancer Care Alliance / University of Washington, Seattle

98373

Northwest Medical Specialties, Puyallup

06520

Yale Cancer Center, New Haven

06856

The Whittingham Cancer Center / Norwalk Hospital, Norwalk

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT01969643 - A Safety Study of SGN-LIV1A in Breast Cancer Patients | Biotech Hunter | Biotech Hunter